中国神经再生研究(英文版) ›› 2021, Vol. 16 ›› Issue (9): 1764-1765.doi: 10.4103/1673-5374.306070

• 观点:退行性病与再生 • 上一篇    下一篇

性别、载脂蛋白E4和阿尔茨海默氏症:精准医学时代对药物发现的反思

  


  • 出版日期:2021-09-15 发布日期:2021-02-05

Sex, ApoE4 and Alzheimer’s disease: rethinking drug discovery in the era of precision medicine

Manish D. Paranjpe#, Jason K Wang#, Yun Zhou*   

  1. Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, USA (Paranjpe MD, Wang JK)
    Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA (Zhou Y)
  • Online:2021-09-15 Published:2021-02-05
  • Contact: Yun Zhou, PhD, yunzhou@wustl.edu.

摘要: https://orcid.org/0000-0001-9135-336X  (Yun Zhou)

Abstract: Alzheimer’s disease (AD) is the most common cause of dementia and presents with an insidious onset and long prodromal period. Despite billions spent on clinical trials and decades of research, there are currently no disease modifying therapies approved for AD.